View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
August 9, 2021

India authorises J&J’s Covid-19 vaccine for emergency use

To be made available in India through an alliance with Biological E, the vaccine’s delivery timeline is yet to be decided.

India has approved Johnson & Johnson’s (J&J) single-dose Covid-19 vaccine for emergency use, expanding the total number of anti-SARS-CoV-2 vaccines authorised in the country to five.

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

J&J submitted an application seeking emergency use authorization (EUA) for the vaccine to the Government of India on 5 August this year.

The company said it was too early to give a delivery timeline, Reuters reported. The vaccine doses will be made available in India through a partnership with the domestic company Biological E .

In a statement, J&J said: “This is an important milestone that paves the way to bringing our single-dose Covid-19 vaccine to the people of India, and the rest of the world, through a collaboration with Biological E .

Biological E will be an important part of our global supply chain network, helping to supply our Johnson & Johnson Covid-19 vaccine through the extensive collaborations and partnerships we have with governments, health authorities and organisations such as Gavi and the COVAX Facility.”

The EUA submission in India is based on efficacy and safety results from the Phase III Ensemble clinical trial, which showed that the vaccine had 85% efficiency in preventing severe Covid-19 in all regions analysed.

Furthermore, the single-dose vaccine was demonstrated to offer protection against Covid-19 linked hospitalisation and death, from 28 days after the inoculation.

Last month, J&J reported that its single-dose Covid-19 vaccine stimulated robust, continued neutralising antibody activity against the Delta (B.1.617.2) variant, as well as other SARS-CoV-2 viral variants.

The data was from an analysis of blood samples collected from a subset of subjects in the Ensemble trial.

Apart from the J&J vaccine, Indian health authorities have authorised the use of Covid-19 vaccines developed by AstraZeneca , Bharat Biotech , Russia’s Gamaleya Institute and Moderna .

Moderna received approval for its vaccine in June but the vaccine doses have not arrived in the country so far due to legal protection sought by the company, Reuters added.

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology